Search Results
Your search for �V" matches 1250 pages
Showing 351 - 400What You Need to Know About Cancer and the Coronavirus
As a three-time breast cancer survivor, when the COVID-19 pandemic hit the United States this past January, I knew I had to do everything I could to avoid getting the virus. A host of lingering side effects from my surgeries, chemotherapy, and radiation treatments have left me with cardiovascular...
Margetuximab-cmkb: A Novel Agent Overshadowed by an Abundance of Options in HER2-Positive Breast Cancer
It is incredible to reflect upon the scientific advances in the treatment of HER2-positive breast cancer over the past 23 years. Once considered the worst subtype of breast cancer, HER2-positive disease is now associated with the best long-term outcomes in this age of targeted treatments. With a...
Expert Point of View: Alexander Eggermont, MD, PhD
Formal discussant of CheckMate 915, Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, suggested that the lower doses of ipilimumab used in the current study may explain the lack of effect on relapse-free survival. The...
Comparing Nivolumab Plus Ipilimumab vs Nivolumab Alone in Resected Stage III to IV Melanoma
The addition of ipilimumab to nivolumab failed to improve outcomes compared with nivolumab alone as adjuvant therapy for resected melanoma, according to the results of the CheckMate 915 trial, presented at the virtual edition of the American Association for Cancer Research (AACR) Annual Meeting...
Phase II Trial Reports Anticancer Activity With Novel FGFR Inhibitor in Advanced Intrahepatic Cholangiocarcinoma
Futibatinib—a selective, fibroblast growth factor receptor (FGFR) inhibitor—demonstrated anticancer activity in patients with advanced intrahepatic cholangiocarcinoma and FGFR2 fusions or rearrangements. These findings are based on the primary results of the phase II FOENIX-CCA2 trial, which were...
Expert Point of View: Angeles Alvarez Secord, MD
The invited discussant of the phase II feMMe trial1 was Angeles Alvarez Secord, MD, Professor of Obstetrics and Gynecology, Duke University School of Medicine, Durham, North Carolina. She noted that, because of its “alarming” increase in incidence and mortality, endometrial cancer is “a critically...
Hormonal Intrauterine Device Under Study for Managing Early Endometrial Cancer
Disease regression was observed in 82% of women with endometrial hyperplasia with atypia and 43% of women with endometrial cancer after treatment for 6 months with a hormonal intrauterine device in a phase II study reported during the virtual edition of the Society of Gynecologic Oncology (SGO)...
Increasing Cervical Cancer Prevention and Care in Nepal
A new JCO Global Oncology special article details the process and results of a Multidisciplinary Cervical Cancer Prevention Course that ASCO volunteers led in Nepal, where cervical cancer remains the most common cancer among women and most patients present with an advanced stage of the disease.1...
PENELOPE-B: Palbociclib for Residual Invasive HR-Positive, HER2-Negative Early Breast Cancer After Neoadjuvant Chemotherapy
As reported in the Journal of Clinical Oncology by Sibylle Loibl, MD, PhD, and colleagues, the phase III PENELOPE-B trial has shown that palbociclib plus endocrine therapy did not improve invasive disease–free survival vs placebo plus endocrine therapy in patients with residual invasive hormone...
Georgina V. Long, MD, PhD, on Melanoma: Nivolumab Plus Ipilimumab vs Nivolumab Alone
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, University of Sydney, discusses results of the CheckMate 915 trial, which may reinforce nivolumab as an adjuvant standard of care in patients with stage IIIB–D/IV melanoma, with or without complete lymphadenectomy (Abstract CT004).
Addition of Alpelisib to Fulvestrant for PIK3CA-Mutant, HR-Positive, HER2-Negative Advanced Breast Cancer: Patient-Reported Outcomes
In an analysis from the PIK3CA-mutant cohort of the phase III SOLAR-1 trial reported in the Journal of Clinical Oncology, Eva Ciruelos, MD, PhD, and colleagues found that the addition of alpelisib to fulvestrant was not associated with significant worsening of global health status/quality of life...
Novel Insights in Myelodysplastic Syndromes: Highlights From 2020 ASH Meeting
To complement The ASCO Post’s comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel clinical trial findings in myelodysplastic syndromes (MDS). For full details of...
Cardiovascular Concerns With the Use of VEGFR Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor (VEGFR) have proved to be effective drugs in the treatment of many solid tumors. However, their clinical benefit may come at the cost of cardiovascular toxicity if clinicians are not vigilant and proactive. During...
Lenvatinib/Pembrolizumab Improves Survival in Advanced Endometrial Cancer
In the first report from the pivotal phase III KEYNOTE-775/Study 309 trial, the combination of lenvatinib, a multikinase inhibitor of VEGFR1, VEGFR2, and VEGFR3 kinases, and pembrolizumab significantly improved multiple outcomes compared with standard single-agent chemotherapy in patients with...
Yoga in Oncologic Care: An Evidence-Based Treatment to Improve Outcomes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Increasingly, patients with cancer desire nonpharmacologic strategies for managing their...
Pembrolizumab in First-Line Treatment of Metastatic Clear Cell and Non–Clear Cell Renal Cell Carcinoma
The treatment paradigm for patients with metastatic renal cell carcinoma has undergone a dramatic shift over the past few years, improving outcomes for many patients but leaving many unanswered questions as to how to optimally choose the best treatment for an individual patient. The changes are...
IMbrave150: A New Standard of Care to Treat Hepatocellular Cancers?
In 2007, sorafenib became the first approved systemic therapy for hepatocellular cancers and the first agent to improve overall survival in these patients.1 In a similar multikinase inhibitor strategy, lenvatinib was found to be noninferior to sorafenib in overall survival in the same patient...
EV-301 and EV-201 Trials: Enfortumab Vedotin-ejfv Improves Survival in Metastatic Urothelial Cancer
Enfortumab vedotin-ejfv continues to move the needle forward as a validated treatment option for advanced urothelial carcinoma. At the 2021 Genitourinary Cancers Symposium, results from the phase III EV-301 study1 and EV-201 Cohort 22 provided support for the use of this agent in both patients...
ASCO and Friends of Cancer Research Recommend Expanding Patient Access to Cancer Clinical Trials by Further Broadening Eligibility Criteria
ASCO and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients.1 The joint recommendations are detailed in a series of articles...
Studies Provide Guidance on the Use of Blinatumomab in Pediatric Acute Lymphoblastic Leukemia
Monotherapy with blinatumomab as consolidation therapy before allogeneic stem cell transplant appears to be the optimal treatment for children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (ALL), according to an international phase III trial that compared this approach...
Expert Point of View: John C. Krauss, MD
Invited discussant John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, said he was impressed by the “rapidity with which the NRG-GI002 trial accrued,” which was about 10 months.1 “Equally...
CLEAR Trial: Is Lenvatinib Plus Pembrolizumab the Best First-Line Immunotherapy Doublet in Metastatic Renal Cell Carcinoma?
At the 2021 Genitourinary Cancers Symposium, Motzer et al presented the clinical results of the CLEAR trial, adding a novel regimen, lenvatinib plus pembrolizu-mab, to the growing armamentarium of first-line treatments for patients with metastatic clear cell renal cell carcinoma (RCC). The...
In Case You Missed It: Brief Highlights From ASH 2020
In case you missed these while attending the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, below is a sampler of highlights that were not included in our first round of meeting coverage. Many of these reports are on early-phase clinical trials of agents that may raise...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Kenya
The ASCO Post is pleased to continue this occasional special focus on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Kenya. The aim of this special feature is to highlight the global cancer burden for various countries of the...
Joseph V. Simone, MD, Visionary Pediatric Oncologist and ‘Quintessential Mentor,’ Dies at 85
When Joseph V. Simone, MD, was 6 years old, he had his first experience with the death of a child. His 9-month-old brother became sick with the croup and was taken to the nearby children’s hospital, where he died a few days later, leaving Dr. Simone and his family devastated. Caring for sick...
B-Cell and T-Cell Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the assessment and treatment of patients with B-cell and T-cell non-Hodgkin...
Addition of Lenalidomide to R-CHOP in Newly Diagnosed Patients With DLBCL
In a phase II signal-seeking trial (ECOG-ACRIN E1412) reported in the Journal of Clinical Oncology, Grzegorz S. Nowakowski, MD, and colleagues found that the addition of lenalidomide (R) to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2CHOP) improved outcomes...
Novel Insights Into Multiple Myeloma
“Knowledge has a beginning but no end.” —Geeta Iyengar To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for...
Predicting Postoperative Recurrence in Stage I to III Colorectal Cancer With Circulating Tumor DNA
Patients with stage I to III colorectal cancer who have a high risk for recurrence may be identified by serial testing of circulating tumor DNA (ctDNA) after resection, according to a study in which ctDNA proved more reliable than carcinoembryonic antigen (CEA) surveillance or standard radiologic...
Giorgio V. Scagliotti, MD, PhD, on Doubling the Lung Cancer Cure Rate by 2025: A Realistic Goal
Giorgio V. Scagliotti, MD, PhD, of the University of Torino, talks about why he believes that many more patients with lung cancer can be cured within the next 4 years, given decreases in mortality rates, widespread use of targeted treatments and immunotherapies, and earlier diagnoses as a result of ...
Huntsman Cancer Institute Appoints Cancer Center Research Program Leaders
Huntsman Cancer Institute (HCI) at the University of Utah recently announced that Jay Gertz, PhD, and Trudy G. Oliver, PhD, have accepted invitations to serve as co-leaders of HCI Comprehensive Cancer Center research programs. Dr. Gertz will serve alongside Jared Rutter, PhD, as co-leader of the...
AMA Statement on the Nominations of Xavier Becerra, JD, as HHS Secretary and Vivek Murthy, MD, as U.S. Surgeon General
Russ Kridel, MD, Chair of the American Medical Association (AMA) Board of Trustees, recently released the following statement on December 17, 2020: The American Medical Association strongly supports the nominations of Xavier Becerra, JD, to be the next Secretary of Health and Human Services (HHS)...
Expert Point of View: Suzanne Lentzsch, MD, PhD
IFM 2009 showed that autologous stem cell transplant (ASCT) combined with lenalidomide, bortezomib, and dexamethasone (RVd) results in a significantly better progression-free survival than RVd alone in newly diagnosed patients with myeloma.1 “The data favor immediate ASCT, as transplant resulted in ...
Long-Term Follow-up of IFM 2009 Confirms Benefit of Front-Line Transplant in Myeloma
The benefit of autologous transplantation in newly diagnosed multiple myeloma has been confirmed by follow-up of the IFM 2009 trial, reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition by Aurore Perrot, MD, PhD, Assistant Professor of Hematology at the Cancer...
IMpower133 Update: Atezolizumab Plus Carboplatin/Etoposide for Extensive-Stage Small Cell Lung Cancer
As reported in the Journal of Clinical Oncology by Stephen V. Liu, MD, and colleagues, an updated overall survival analysis in the phase I/III IMpower133 trial showed continued benefit with the addition of atezolizumab to carboplatin/etoposide as first-line treatment in patients with...
Evolving Landscape of First-Line Therapy for Metastatic Renal Cell Carcinoma
In the past 3 years, we have seen a dramatic shift in the treatment paradigm for first-line therapy for metastatic clear cell renal cell carcinoma. Multiple phase III clinical trials have demonstrated improved efficacy with combinations compared with sunitinib, leading to the regulatory approval of ...
Tenna V. Henriksen, PhD Candidate, on Colorectal Cancer: Circulating Tumor DNA Analysis to Improve Treatment
Tenna V. Henriksen, PhD Candidate, of Aarhus University, discusses her findings on how circulating tumor DNA may help assess recurrence risk and the benefit of adjuvant therapy, and more quickly detect early relapse after treatment in patients with colorectal cancer (Abstract 11).
Risk Categories for Pediatric Patients With Medulloblastoma
In an analysis from the international phase III SJMB03 trial reported in the Journal of Clinical Oncology, Gajjar et al identified lower- and higher-risk groups of pediatric patients with medulloblastoma based on molecular and clinical risk factors. Study Details SJMB03 is a phase III trial of...
Postsurgical Disease Recurrence in Stage I to III Colorectal Cancer May Be Predicted by ctDNA
Patients with stage I to III colorectal cancer and a high risk for disease recurrence may be identified by serial testing of circulating tumor DNA (ctDNA) after resection, according to a study in which ctDNA was more reliable than carcinoembryonic antigen (CEA) surveillance or standard radiologic...
Left Anterior Descending Coronary Artery Radiation Exposure, Cardiac Events, and Mortality in NSCLC
In a retrospective cohort analysis reported in JAMA Oncology, Atkins et al identified a volume (V, percent) of exposure of the left anterior descending (LAD) coronary artery to a radiation dose (V15 Gy ≥10%) that is an independent risk factor for major adverse cardiac events and all-cause mortality ...
Reducing Disparities in Cancer Care for Sexual and Gender Minority Patients
Although efforts have been made by various medical societies, including ASCO, over the past decade to address the needs of sexual and gender minorities in the cancer care setting, research shows that lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients continue to face...
Joyce V. Lee, PhD, on Triple-Negative Breast Cancer: MYC as a Predictor of Treatment Response
Joyce V. Lee, PhD, of the University of California, San Francisco, discusses data that suggest the MYC oncogene may indicate whether a patient with triple-negative breast cancer will respond to immunotherapy. Dr. Lee’s study is the first to describe MYC downregulation of MHC-I and to demonstrate...
Changes in Care and Well-Being Among Patients With Cancer During Initial Stage of the COVID-19 Pandemic
In a Dutch study reported in JAMA Oncology, van de Poll-Franse et al found that a substantial proportion of patients with cancer had changes in care within 4 to 6 weeks after the first announcement of a COVID-19–related lockdown. Patients with cancer surveyed reported levels of quality of life,...
Continued Progression-Free and Overall Survival Superiority of First-Line Pembrolizumab/Axitinib vs Sunitinib
As reported in The Lancet Oncology by Thomas Powles, MD, of Barts Cancer Institute, London, and colleagues, extended follow-up of the phase III KEYNOTE-426 trial shows continued progression-free and overall survival superiority with pembrolizumab/axitinib vs sunitinib alone in first-line treatment ...
The Lung Microbiome May Affect Lung Cancer Pathogenesis and Prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced-stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.1 “The...
Researchers Join $10 Million Project to Better Understand Sex Differences in Brain Cancer Outcomes
Researchers from Penn State College of Medicine are participating in a $10 million project to better understand why men and women with a common and deadly type of brain cancer have different survival rates. The investigators hope the study results can be used to develop new therapeutic approaches...
Complexity of Designing Clinical Trials for Sarcoma: Shifting Focus to Constellation of Subtypes
Sarcoma has bedeviled researchers for many years because of its heterogeneity. Sarcoma encompasses more than 100 different subtypes, which makes it difficult to design studies to identify effective therapies. As researchers dig deeper into the constellation of subtypes of sarcoma, some therapies...
Native American Ancestry May Impact Somatic Alterations Among Latin American Patients With Lung Cancer
A research brief by Carrot-Zhang et al published in Cancer Discovery investigating inherited lung cancer risk—especially in nonsmokers—in Latin America has found that independent of smoking status, variation in EGFR and KRAS mutation frequency in Latin American patients with lung cancer was...
Venetoclax in Combination Therapy for Untreated Acute Myeloid Leukemia
On October 16, 2020, venetoclax was granted regular approval for use in combination with azacitidine, decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults aged 75 years or older or those with comorbidities precluding intensive induction...
Impact of COVID-19 on Cancer Care in India
With the announcement of a complete nationwide lockdown on March 25, 2020, to prevent the spread of COVID-19, a lot of unprecedented events came into being in India. The National Health Mission reported a 69% reduction in measles, mumps, and rubella vaccination in children; a 21% reduction in...
